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ABSTRACT
Metabolic diseases and comorbidities represent an
ever-growing epidemic where multiple cell types
impact tissue homeostasis. Here, the link between
the metabolic and gene regulatory networks was
studied through experimental and computational
analysis. Integrating gene regulation data with a
human metabolic network prompted the establish-
ment of an open-sourced web portal, IDARE
(Integrated Data Nodes of Regulation), for visualizing
various gene-related data in context of metabolic
pathways. Motivated by increasing availability of
deep sequencing studies, we obtained ChIP-seq
data fromwidely studied human umbilical vein endo-
thelial cells. Interestingly, we found that association
of metabolic genes with multiple transcription
factors (TFs) enriched disease-associated genes.
To demonstrate further extensions enabled by
examining these networks together, constraint-
based modeling was applied to data from human
preadipocyte differentiation. In parallel, data on
gene expression, genome-wide ChIP-seq profiles
for peroxisome proliferator-activated receptor
(PPAR) c, CCAAT/enhancer binding protein (CEBP)
a, liver X receptor (LXR) and H3K4me3 and
microRNA target identification for miR-27a, miR-29a
and miR-222 were collected. Disease-relevant key
nodes, including mitochondrial glycerol-3-phosphate
acyltransferase (GPAM), were exposed from meta-
bolic pathways predicted to change activity by
focusing on association with multiple regulators. In
both cell types, our analysis reveals the convergence
of microRNAs and TFs within the branched chain
amino acid (BCAA) metabolic pathway, possibly
providing an explanation for its downregulation in
obese and diabetic conditions.
INTRODUCTION
Several diseases caused by dysfunction in metabolism have
become prevalent in human populations worldwide.
Among these, cardiovascular disease (CVD) represents
the leading cause of death worldwide. Obesity is a major
risk factor for CVD, in particular when accompanied with
insulin resistance, hypertension and altered blood lipid
proﬁles (1). These in combination are referred to as the
metabolic syndrome that also confers risk to develop
diabetes and cancer (1).
High-quality genome-scale metabolic reconstructions
are now available that represent the entire network of
metabolic reactions a given organism is known to
exhibit (2,3). Metabolic ﬂuxes within the network adapt
according to enzyme activity, substrate, cofactor, energy,
metabolite and product availability as well as posttransla-
tional regulation (4,5). Current technologies allow the
characterization of global phenotypes on the transcrip-
tome level through deep sequencing of RNA and DNA
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molecules. However, global measurements of proteome
activity or metabolic ﬂuxes remain a bottleneck.
To address the latter limitation, it is possible to leverage
the ability of mathematical models to integrate various
data types to reveal central changes in metabolism.
These mathematical representations allow the computa-
tion of physiological states. For estimating reaction
activities, a method was proposed (6) where the expression
levels serve as a soft-constraint to favor consistent solu-
tions in concordance with the mass conservation in the
metabolic network.
Alterations in the expression status are an initial step
for a metabolic shift and can serve as a predictor of the
metabolic activity cells are able to sustain. For this reason,
the regulator molecules actuating this shift represent can-
didate therapeutic targets. In adipocytes, two transcrip-
tion factors (TFs), peroxisome proliferator-activated
receptor g (PPARg) and CCAAT/enhancer binding
protein a (CEBPa), have been shown to be the key regu-
lators: they are required to initiate terminal differentiation
and are sufﬁcient to convert other cell types to adipocytes
(7), manifested through their genome-wide binding proﬁle
that positions them as master regulators of the adipocyte
expression proﬁle (8–10). Several antidiabetic drugs have
been developed that activate PPARg (11). The widely used
CVD drugs statins on the other hand impact cholesterol
levels through genes regulated by the signal-responsive
TFs sterol-regulatory element binding factors (SREBFs)
and liver X receptors (LXRs) (12). It is highly likely that
interactions among TFs could play a role in disease, yet
less is known so far how their targets overlap. Recent
studies have also placed attention on the role of
noncoding RNA regulators known as microRNAs
(miRNAs) during adipocyte differentiation of cell
culture and in vivo models (13,14), identifying counteract-
ing regulators such as the miR-27 family and let-7 (15–18).
We have recently identiﬁed several miRNAs as primary
PPARg target genes in mouse adipocytes (19), yet it
remains unclear to what extent these different regulators
converge to control the metabolic phenotype and whether
identifying their convergence points could improve thera-
peutic interventions.
The Encyclopedia of DNA Elements (ENCODE)
project has built an extensive list of functional elements
in the human genome, including regulatory elements
bound by TFs that control gene activity (20). Human um-
bilical vein endothelial cells (HUVECs) belong to the
panel of ENCODE cell types with most data available
and are also widely used as a model cell line in CVD
research. Here, we hypothesized that observing the regu-
lation of metabolic genes via multiple regulators (epigen-
etic, transcriptional and posttranscriptional) could
indicate a plausible high relevance in a disease context.
Moreover, to delineate the metabolic activity shifts
affected by these key nodes, such an integrative analysis
could become informative coupled with mathematical
modeling of reaction activities. To allow data sources of
gene regulation [such as ENCODE (20)] and metabolic
network models (2,3) to be explored in an integrative
manner, we used a tripartite graph representation and
developed an interactive web portal, Integrated Data
Nodes of Regulation (IDARE, http://systemsbiology.
uni.lu/idare.html, see User Guide in Supplementary
Material), that can be used to visualize global or tissue-
speciﬁc data. This integrative experimental and computa-
tional analysis allowed us to address the connectivity
between the human regulatory and metabolic networks.
Using just the overlap of TF-gene associations and the
metabolic network, we observed a strong enrichment of
disease-associated nodes among genes that show TF
binding in multiple HUVEC ChIP-seq studies, including
the nitric oxide synthase (NOS) gene family. We collected
further experimental data on TFs and miRNAs in adipo-
cytes differentiated from Simpson–Golabi–Behmel
syndrome (SGBS) preadipocyte cell line, an established
model for human adipogenesis (21). Interestingly, each
of the previously characterized dyslipidemia genes
LDLR (LDL receptor) (22), LPIN1 (lipin 1) (23) and
LPL (lipoprotein lipase) (24) that belong to the
triacylglycerol synthesis and release pathway are high-
lighted as shared TF- and miRNA-associated genes.
Moreover, the cell fate determining TFs were observed
to form a multi-TF feed-forward loop with binding sites
nearby genes from the cholesterol synthesis and fatty acid
activation pathways. Finally, the convergence of miRNAs
and TFs highlight the branched-chain amino acid (BCAA)
metabolism as a key nonlipid pathway for which altered
regulation by the factors studied here may provide an ex-
planation for its association with obesity and diabetes.
MATERIALS AND METHODS
Cell culture and differentiation
The human preadipocyte cell line isolated from a
Simpson-Golabi-Behmel syndrome patient (SGBS) have
previously been shown to be in many ways identical to
differentiated primary adipocytes from healthy donors
but maintain their differentiation capacity longer than
other isolated cells (21), therefore representing an
optimal model system for high-throughput analysis. The
SGBS cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM)/Nutrient Mix F12 (Gibco, Paisley,
UK) containing 8mg/l biotin, 4mg/l pantothenate,
0.1mg/ml streptomycin and 100U/ml penicillin (OF
medium) supplemented with 10% FBS in a humidiﬁed
95% air/5% CO2 incubator. The cells were seeded into
culture medium ﬂasks or plates, which were coated with
a solution of 10 ml/ml ﬁbronectin and 0.05% gelatine in
phosphate-buffered saline (PBS). Conﬂuent cells were
cultured in serum-free OF medium for 2 days followed
by stimulation to differentiate with OF media supple-
mented with 0.01mg/ml human transferrin, 200 nM T3,
100 nM cortisol, 20 nM insulin, 500 mM IBMX (all from
Sigma-Aldrich) and 100 nM rosiglitazone (Cayman
Chemical, Ann Arbor, USA). After day 4, the
differentiating SGBS cells were kept in OF media supple-
mented with 0.01mg/ml human transferrin, 100 nM
cortisol and 20 nM insulin. SGBS cells differentiate
within 10–12 days as determined by microscopic analysis
(Oil red O staining). At this time point, the cells are ﬁlled
with small-sized lipid droplets and are most responsive,
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whereas at later time points (20 days), the lipid droplets
fuse and cells are less active (Dr Martin Wabitsch,
personal communication). RNA samples were collected
at 0, 4, 8 and 12 h and on days 1, 3 and 12 of differenti-
ation and chromatin samples from day 0 (H3K4me3) and
day 10 (TFs and H3K4me3). To ﬁnd LXR-responsive
genes, the day 10 differentiated SGBS cells were
stimulated with 1 mM T0901317 for 4 h (synthetic agonist
for LXRs), while control cells received DMSO (ﬁnal con-
centration 0.1%).
miRNA transfection
MiRNA mimics for miR-27a, miR-29a and miR-222
(Thermo Scientiﬁc Dharmacon, Colorado, USA) or a
scrambled double-stranded siRNA sequence as control
(siCtrl) (Eurogentec, Lie`ge, Belgium) were introduced
into 4 days differentiated SGBS adipocytes using
Lipofectamine RNAiMAX reagent (Invitrogen, Halle,
Belgium) according to manufacturer’s instructions.
Shortly, miRNA mimics or siRNAs were mixed with
Lipofectamine RNAiMAX reagent, incubated for 20min
and diluted with plain DMEM-F12 medium to a ﬁnal
concentration of 100 nM. The ﬁrst differentiation
medium was replaced by the transfection mixture and
incubated for 2 h before changing to the second differen-
tiation medium (see above). Twenty-four hours after
transfection, the cells were collected for RNA extraction.
RNA extraction and real-time quantitative polymerase
chain reaction
Total RNA was extracted using TriSure (Bioline, London,
UK). One milliliter of TRIsure was added per a conﬂuent
six-well to lyse the cells. RNA was extracted with 200 ml of
chloroform and precipitated from the aqueous phase with
400 ml of isopropanol by incubating at 20C overnight.
cDNA was synthesized by using 1 mg of total RNA,
0.5mM dNTPs, 2.5mM oligo-dT18 primer, 1U/ml
RiboLock RNase Inhibitor (Fermentas, Vilnius,
Lithuania) and 10U/ml M-MuLV Reverse Transcriptase
(Fermentas) for 1 h at 37C. The reaction was stopped by
10-min incubation at 70C. Real-time quantitative poly-
merase chain reaction (RT-qPCR) was performed with
Applied Biosystems 7500 Fast Real-Time PCR System
using Absolute Blue qPCR SYBR Green Low ROX Mix
reagent (Thermo Fisher Scientiﬁc, Surrey, UK). Five
microliters of cDNA template was used with 1 ml of
gene-speciﬁc primer pairs (10 mM) and 10 ml of the qPCR
SYBR mixture in a ﬁnal reaction volume of 20 ml. The
PCR reaction started with 15min at 95C to activate
the polymerase. The PCR cycling conditions were as
follows: 40 cycles, of which each was composed of
15 s at 95C, 15 s at 55C and 30 s at 72C. Fold inductions
were calculated using the formula 2(Ct), where Ct
is [Ct(target mRNA)Ct(RPL13A)]differentiated [Ct(target mRNA)
Ct(RPL13A)] and the Ct is the cycle at which the threshold
is crossed. PCR product quality was monitored using
post-PCR melt curve analysis. The primer sequences are
provided in Supplementary Table S1.
miRNA assays
The miRNA detection was performed by using TaqMan
MicroRNA Reverse Transcription Kit with TaqMan
MicroRNA Assays (Applied Biosystems). The miRNA
cDNA synthesis and miRNA real-time PCR were done
following manufacturer’s instructions and by using an
Applied Biosystems 7500 Fast Real-Time PCR System.
Relative expression levels in the undifferentiated and
the 5-day differentiated adipocytes were calculated
using the formula 2(Ct), where Ct is [Ct(target
miRNA)Ct(U6)]differentiated [Ct(target miRNA)Ct(U6)]undif-
ferentiated and the Ct is the cycle at which the threshold is
crossed.
Microarray proﬁling
Total RNA in triplicates from the differentiation time
series, LXR agonist stimulation and the miRNA transfec-
tions were processed according to the manufacturer
instructions to prepare cDNA that was hybridized on
microarrays (for the time series and ligand stimulation,
the array hybridizations were performed on Illumina
HT-12 v3 arrays at the Turku Centre for Biotechnology,
Microarray and sequencing facility; for the miRNA trans-
fections, on Illumina HT-12 v4 arrays at DNA Vision,
Charleroi, Belgium). The raw data ﬁles were processed
and quality controlled using the R/Bioconductor lumi
package. Raw and normalized expression values are avail-
able via GEO (GSE41578). Genes that had a detection P
<0.05 were selected for statistical analysis performed
using the limma package. The F-test was used to assess
signiﬁcance of overall dynamic response over the differen-
tiation and a two-tailed t-test to compare speciﬁc time
points to day 0 undifferentiated cells (Benjamini–
Hochberg adjusted P <0.01 was considered signiﬁcant).
For the miRNA transfections, statistical analysis was
based on t-test signiﬁcance comparing mean expression
levels on miRNA transfection to a scrambled siRNA
control transfection, and similarly the LXR agonist-
treated cells were compared with solvent-treated cells.
The expression proﬁles of metabolic genes or TFs were
clustered for visualization using self-organizing maps
[GEDI software (25)] and AutoSOME (26) as instructed
in the tool documentation. Enriched pathways from the
human metabolic reconstruction (2) were determined
using a hypergeometric test testing for overrepresentation.
Genes from Gene Ontology categories with similar gene
numbers as Recon1 (1040) were obtained using the GO
Online SQL Environment (http://www.berkeleybop.org/
goose), as of 12 August 2013: cell projection (747),
envelope (630), locomotion (775) and receptor activity
(464). The number of probes detected in the array is
indicated in brackets for each category from a total of
12 756 detected probes.
miRNA array proﬁling
Total RNA samples from time points day 0, day 1, day 3
and day 12 of the differentiation time series used for
mRNA array analysis (see above) were also used to
proﬁle miRNAs using miChip arrays (v.11.0) arrays (27)
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at the EMBL Genomics Core facility at Heidelberg. The
raw signal values from total RNA array hybridizations
were median normalized and then further normalized to
the respective signals from day 0 samples. Only probes
corresponding to mature human miRNAs were included
in the analysis.
Chromatin immunoprecipitation
Nuclear proteins were cross-linked to DNA by adding
formaldehyde directly to the medium to a ﬁnal concentra-
tion of 1% for 8min at room temperature. Cross-linking
was stopped by adding glycine to a ﬁnal concentration of
0.125M and incubating for 5min at room temperature on
a rocking platform. The medium was removed and the
cells were washed twice with ice-cold PBS. The cells
were then collected in lysis buffer [1% sodium dodecyl
sulphate (SDS), 10mM EDTA, protease inhibitors,
50mM Tris–HCl, pH 8.1] and the lysates were sonicated
by a Bioruptor UCD-200 (Diagenode, Liege, Belgium) to
result in DNA fragments of 200–500 bp in length. Cellular
debris was removed by centrifugation and the lysates were
diluted 1:10 in ChIP dilution buffer (0.01% SDS, 1.1%
Triton X-100, 1.2mM EDTA, 167mM NaCl, protease
inhibitors, 16.7mM Tris–HCl, pH 8.1). Chromatin solu-
tions were incubated overnight at 4C with rotation with
antibodies against H3K4me3 (4ml per immunopre-
cipitation (IP) of 17-614, Millipore, Billerica, MA,
USA), PPARg (mixture of 0.5ml per IP of sc-7196x,
Santa Cruz Biotechnologies, Santa Cruz, CA, USA and
5 ml per IP of 101700, Cayman, Ann Arbor, MI USA),
CEBPa (5 ml per IP of sc-61, Santa Cruz
Biotechnologies) and LXRa (5 ml per IP, kind gift from
Eckardt Treuter, Karolinska Institute, Stockholm,
Sweden). The LXR antibody recognizes also LXRb that
maintains a constant low level of expression during differ-
entiation. The immuno complexes were collected with
20 ml of MagnaChIP protein A beads (Millipore) for 1 h
at 4C with rotation. Nonspeciﬁc background was
removed by incubating the MagnaChIP protein A beads
overnight at 4C with rotation in the presence of bovine
serum albumin (250 mg/ml). The beads were washed se-
quentially for 3min by rotation with 1ml of the following
buffers: low salt wash buffer (0.1% SDS, 1% Triton X-
100, 2mM EDTA, 150mM NaCl, 20mM Tris–HCl, pH
8.1), high salt wash buffer (0.1% SDS, 1% Triton X-100,
2mM EDTA, 500mM NaCl, 20mM Tris–HCl, pH 8.1)
and LiCl wash buffer (0.25M LiCl, 1% Nonidet P-40, 1%
sodium deoxycholate, 1mM EDTA, 10mM Tris–HCl, pH
8.1). Finally, the beads were washed twice with 1ml of TE
buffer (1mM EDTA, 10mM Tris–HCl, pH 8.1). The
immuno complexes were then eluted by adding 500 ml of
elution buffer (25mM Tris–HCl, pH 7.5, 10mM EDTA,
0.5% SDS) and incubating for 30min on rotation. The
cross-linking was reversed and the remaining proteins
were digested by adding 2.5ml of proteinase K
(Fermentas) to a ﬁnal concentration of 80 mg/ml and
incubating overnight at 65C. The DNA was recovered
by phenol/chloroform/isoamyl alcohol (25:24:1) extrac-
tions and precipitated with 0.1 volume of 3M sodium
acetate, pH 5.2, and 2 volumes of ethanol using
glycogen as carrier. Immunoprecipitated chromatin
DNA was then used as a template for real-time quantita-
tive PCR or for library preparation and sequencing
(performed at EMBL Core facility).
PCR of chromatin templates
Real-time quantitative PCR of ChIP templates was per-
formed using chromatin-region–speciﬁc primers in a total
volume of 20 ml with Applied Biosystems 7500 Fast Real-
Time PCR System using Absolute Blue qPCR SYBR
Green Low ROX Mix reagent (Thermo Fisher Scientiﬁc,
Surrey, UK). The PCR cycling conditions were preincu-
bation for 15min at 95C, 40 cycles of 15 s at 95C, 15 s at
55C and 30 s at 72C and a ﬁnal elongation for 10min at
72C. Relative association of chromatin-bound protein
was calculated using the formula 2(Ct)*100, where
Ct is Ct(output)Ct(IgG control), output is the DNA
immunoprecipitated with TF-speciﬁc antibodies and IgG
control is the DNA from immunoprecipitations using
nonspeciﬁc control antibody. The primer sequences are
provided in Supplementary Table S1.
Discretization of array expression values and
constraint-based model
Metabolic changes resulting from human SGBS
preadipocyte cell differentiation were qualitatively pre-
dicted from gene expression data using an implementation
of the constraint-based method by Shlomi et al. (6).
Constraint-based modeling is a widely used mathematical
approach for the description and analysis of metabolic
networks. It relies on the stoichiometric structure and
does not require detailed kinetic parameters. By
assuming steady state for the intracellular metabolites,
the respective dynamic balance equations can be simpliﬁed
to easy to handle linear equations. Besides the law of
mass conservation, other constraints might be included,
e.g. enzyme capacities, irreversibility information or
measured uptake and secretion rates, as well as optimality
considerations, to further constrain the possible solution
space, i.e. the possible ﬂux values, which can be realized
within the given network structure. Recent efforts, like the
aforementioned applied method of Shlomi et al., focus on
the generation of context-speciﬁc and thus more predictive
models via the additional integration of omics data. A
consistent version of the generic human metabolic model
Recon1 (2) served thereby as modeling platform on which
own microarray data were overlaid as soft-constraints
based on gene-protein-reaction associations to allow the
prediction of network activity distributions. LPIN1 was
missing and owing to its central role in adipocytes, was
added to the model and assigned to the triacylglycerol
pathway. Continuous log2-normalized expression values
were ﬁrst discretized into three categories: lowly expressed
(1), moderately expressed (0) and highly expressed (1)
genes, based on mean expression±0.5*standard devi-
ation cutoffs. These values were mapped to the reactions
contained in Recon1 and used as input for the metabolic
reaction activity prediction.
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Heptamer enrichment analysis and miRNA target
identiﬁcation
To identify heptamer motifs whose frequency is signiﬁ-
cantly different in the 30-untranslated regions (30-UTRs)
of downregulated transcripts, relative to their frequency in
the entire set of 30-UTRs, we considered all RefSeq tran-
scripts for which a corresponding probe set was signiﬁ-
cantly downregulated (P< 0.01, log2-fold change <0.3)
24 h after miRNA mimic transfection. The 30-UTR se-
quences of the RefSeq transcripts were downloaded
from the UCSC genome browser (14.05.2012) and the
human miRNA sequences were obtained from miRBase
release 18 (http://www.mirbase.org/). The enrichment
analysis was performed using a Bayesian model originally
introduced for comparing miRNA frequencies between
samples (28,29) that have been successfully applied to
determine motif enrichments of small RNAs (30,31).
The transcripts for the list of putative target transcripts
of miR-27a, miR-29a and miR-222 were selected based on
two criteria: (i) at least one probe set corresponding to the
transcript was signiﬁcantly downregulated on the respective
miRNA transfection and, (ii) the transcripts 30-UTR con-
tained at least one hit for any of the possible heptameric
reverse complements for the corresponding seed sequences
of miR-27a (CUGUGAA or ACUGUGA), miR-29a (GG
UGCUA, AUGGUGC or UGGUGCU) or miR-222 (AU
GUAGC), respectively.
ChIP-seq analysis
The HUVEC H3K4me3 peak data available from ENCODE
(wgEncodeUwHistoneHuvecH3k4me3StdPkRep1) was over-
lapped with transcription start site (TSS) coordinates from
Refseq to limit the analysis to active genes in HUVECs.
Gene to disease associations were obtained from
DisGeNET (32). A list of endothelial-relevant disease-
associated genes was compiled by combining genes
associated with CVDs, vascular diseases, coronary artery
diseases, cerebrovascular disorders, peripheral arterial oc-
clusive disease and pulmonary arterial hypertension.
ENCODE data from untreated HUVEC cells was
retrieved as peak coordinate ﬁles (UTA cMYC, SYDH
GATA2, SYDH MAX, SYDH cJUN and SYDH
cFOS). Other public data were obtained from the SRA
database as .sra ﬁles (SRR576805 ETS1 from VEGFA
stimulation, SRR351351 MEF2C from statin stimulation,
SRR390745 p65 from TNF stimulation, SRX096362 FLI1
representing an endothelial cell developmental TF,
SRR518265 HIF1A from hypoxia and PPARG samples
SRX032890 and SRX019521, each with their respective
control samples) that were converted to fastq ﬁles using
sratools v.2.1.7. (data from own experiments were already
in fastq format). Raw reads were ﬁrst quality controlled
using the FASTQ software v.0.10.0 (http://www.bioinfor-
matics.babraham.ac.uk/projects/fastqc/). A deviation
from the expected GC-content was observed in the input
sample of SGBS cells and this sample was replaced in the
downstream analysis by a new input obtained from
similarly differentiated cells. All reads that were detected
as read artifacts or that had low-quality base pair calling
were removed and read stacks collapsed using the FASTX
software v.0.0.13 (minimum quality score of phred 10
across the read length was required) (http://hannonlab.
cshl.edu/fastx_toolkit/index.html). The reads that passed
the quality control steps were aligned to the hg19
human genome using the Bowtie (33) software v0.1.25
(one mismatch allowed, maximum three locations in the
genome from which the highest quality match was
reported). The mapping capability with these settings
was tested by aligning all 36-mers of the hg19 fasta
genome available via UCSC and was determined to be
0.88 and used in the subsequent peak-calling step.
SGBS histone data were analyzed using the EpiChIP
software v.0.9.7 (34), where the H3K4me3 signal was
quantiﬁed from 750 to +1250 region centered at
Refseq TSS coordinates. This region was detected to
have the highest signal by window analysis. TF peak de-
tection from SGBS was performed using the Quest
software (35) v.2.4. run in the advanced mode with
default settings applied except for the mappable genome
fraction (set to 0.88) and enrichment (ChIP enrichment set
to 15 and ChIP to background enrichment to 2.5). Fastq
ﬁles and signal tracks from SGBS cells can be accessed via
NCBI GEO (GSE41578). The ﬁnal peak lists were ﬁltered
to remove peaks with log10Qvalue <3. We chose to apply
two cutoffs to detect both low-occupancy (enrichment
>15) and high-occupancy (enrichment >30) binding
sites. In the text, the complete list of low- and high-
occupancy genomic regions (Supplementary Table S2)
has been analyzed unless otherwise speciﬁed. The public
HUVEC ChIP-seq data were processed with default
settings (enrichment 30), which corresponds to settings
used in their respective publications (information was
available for three of ﬁve studies via GEO). To assess
what biological pathways could be most affected by the
given TF, a genomic region enrichment test was per-
formed using the GREAT software (binomial P-value,
false discovery rate (FDR) 1%) (36). The same software
was used to obtain the peak to gene association ﬁles for
analyzing TF convergence on shared targets. The
complete gene association and enrichment term lists for
the SGBS TFs can be found in Supplementary Table S3
Gene metanodes and IDARE web portal
Gene Metanodes (Figure 1) showing gene-related data were
generated withMatlab. Recon1metabolic gene Entrez IDs
were used for data mappings. Based on homogeneous
(HUVEC TFs) or heterogeneous (SGBS) data we
customized the metanode visual appearance. The open
sourced IDARE web portal and its HUVEC and SGBS in-
stances are built using HTML5 standards and javascript
libraries jQuery, highchart.js, bootstrap and cytoscapeweb.
The release contains a conﬁguration-based pythonworkﬂow
responsible for building graph objects fromRecon1 SIF and
XGMMLpathways into javascript object notation ﬁles (full
description on the User Guide provided in the
Supplementary Material). In addition, gene metanode
image ﬁles, annotations from hg19 and time course expres-
sion data are integrated along with reaction and metabolite
relationships. The images and graph object ﬁles are then
deployed to the appropriate directories according to the
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instance workﬂow conﬁgurations. This architecture is ex-
tendable and allows for easy inclusion of other data sets
like HUVEC as well as custom pathways. IDARE instances
can be deployed locally or on web and cloud servers.
RESULTS
Integrating gene regulation data with a human metabolic
reconstruction
A metabolic network typically consists of metabolite and
reaction nodes. To make such models actionable in
context of disease pathways or drug target identiﬁcation,
it becomes useful to integrate the regulation of genes that
catalyze the reactions within the model. We included ver-
satile nodes (referred to as gene metanodes) associated to
reactions, which can represent any gene-centric data col-
lected from different experiments (Figure 1). TF binding
data indicated in ﬁlled circles in the metanode can be
overlaid with the metabolic network that includes rect-
angular nodes representing metabolites and diamonds rep-
resenting reactions. Exempliﬁed using HUVEC data, the
visualization can be used to examine the co-occurrence of
transcriptional regulators. The display options are ﬂexible
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Figure 1. Conceptual overview of the analysis performed that links the regulatory and metabolic networks for exposing disease-relevant genes. A
summary of the data sets and data integration approach is shown. By integrating regulatory network components with metabolic pathways, gene
metanodes shown from the IDARE webportal provide a simple and intuitive means to analyze relationships between the metabolic and regulatory
networks. HUVEC data set: Overlaying TF-binding data indicated in ﬁlled color circles with the metabolic network reaction backbone can be used to
examine the co-occurrence of transcriptional regulators that is informative of likely disease association. Yellow rectangular nodes represent metab-
olites and small orange diamonds represent reactions in the metabolic network. SGBS data set: Often the biological question involves comparison of
phenotypic states. Constraint-based modeling methods, established in context of metabolic reconstructions, can be used as exempliﬁed with data
from adipocyte differentiation. Those pathways that are predicted to shift to an active state in adipocytes compared with preadipocytes are indicated
by the red edge color, yellow and black color correspond to active or inactive reactions in both states. The heatmaps show for each differentiation
time point the gene expression (below) and predicted reaction activity (above) where blue indicates low/absent gene expression or inactive reaction,
gray, moderate expression or undetermined reaction and red stands for highly expressed gene and active reaction, respectively. The regulators can be
added as different shapes. Here, circles above represent the presence (red) or absence (white) of the H3K4me3 marker for active transcription and the
three different polygons to the right represent PPARg (star), CEBPa (triangle) and LXR (square) peak associations (red, present; white, not present).
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including presenting the regulators as different shapes, as
shown in SGBS. Moreover, the edges forming the network
backbone can be colored to represent reaction activity
obtained using constraint-based modeling methods. The
metanode heatmaps show for each differentiation time
point the gene expression (below) and predicted reaction
activity (above). By integrating regulatory network com-
ponents with metabolic pathways, gene metanodes shown
from the IDARE web portal (see Supplementary Data—
IDARE User Guide for further details) provide a simple
and intuitive means to analyze relationships between the
metabolic and regulatory networks.
To illustrate the concept and to test whether such data
could be informative to highlight key parts of the large
metabolic reconstruction networks, we collected ChIP-seq
data from HUVECs that represent the most studied
primary cell type among ENCODE data sets. Using the
H3K4me3 chromatin mark to focus on active loci, we
associated Recon1 genes to TF peaks from 10 studies, 5
collected from NCBI GEO database and 5 available
from ENCODE (see ‘Materials and Methods’ section for
details). Disease information was collected from the
DisGeNET database (32), focusing on endothelial-
relevant disease. Table 1 shows those genes that are
associated with eight or more TFs while the complete
TF and disease association result is shown in
Supplementary Table S4. Interestingly, expressed genes
associated with between seven and nine TFs are >2-fold
enriched in vascular disease-relevant genes, a result
that points to the prominent link between high TF-
mediated gene expression regulation and disease. The
hypergeometric P-values for the different number of
TF associations to Recon1 genes are shown in
Figure 2A, comparing vascular disease-relevant associ-
ations to all disease associations (the observed increasing
trend in signiﬁcance and enrichment apply also when
analysis is not restricted to metabolic genes, data not
shown).
The gene with most disease associations overall, the
endothelial nitric oxide synthase, NOS3 (also known as
ENOS), is visualized in Figure 2B. The release of NO is
a key paracrine signal in the vascular system that is
essential for the regulation of blood ﬂow and pressure
(37). The two other nitric oxide synthases (NOS1 and
NOS2) can catalyze the same reaction to convert
L-arginine to NO. Interestingly, each of these gene
metanodes show multiple TF associations (Figure 2B).
The respective genomic region around NOS3 TSS with
TF signal from the 10 ChIP-seq experiments is shown in
Figure 2C. The other multi-TF–associated nodes in the
proline-arginine metabolic pathway shown in
Supplementary Figure S1 include ALDH4A1 that partici-
pates in multiple amino acid pathways and is known to
cause the autosomal recessive disorder known as type II
hyperprolinemia (38) and MTAP from the coronary
artery disease genome-wide association study (GWAS)
reported locus on chromosome 9 (39). Encouraged by
these ﬁndings, we next evaluated whether the same prin-
ciple generalizes in human adipocytes that represent a key
cell type in obesity and metabolic disease. However, a
more limited set of available genome-wide regulator
proﬁles motivated the collection of experimental data
and in parallel using mathematical predictions based on
the metabolic reconstruction to expose relevant pathways
as described in more detail below.
Predicted metabolic activity changes during adipocyte
differentiation
To outline plausible metabolic activity changes during
adipocyte differentiation using the SGBS cell line, which
represents an established human adipocyte cellular model
isolated from a SGBS patient (21), we leveraged the
constraint-based modeling approach (see ‘Materials and
Methods’ for details) to predict the dynamic activity
changes of metabolic reactions (6). Based on a time-
course measurement of the transcriptome of
differentiating SGBS preadipocytes a dynamic shift is
evident, in particular, in the expression levels of metabolic
genes among which 18%, 2-fold more when compared
with other gene categories with similar numbers of genes
or even with all detected genes (Supplementary Figures S2
and S3) (25,26), are differentially regulated. An overall
trend of increasing levels from day 1 onward results in
219 upregulated metabolic genes by day 12 of differenti-
ation, compared with 98 downregulated genes
(Supplementary Table S5).
As gene expression levels alone are insufﬁcient to
describe the metabolic adaptation that occurs during
terminal differentiation, we used them as soft-constraints
to predict reaction activity for Recon1 (2,6). The predicted
pathway activity changes are shown in Figure 3 and the
complete prediction results for all seven differentiation
time points and the 2469 consistent reactions contained
in Recon1 are provided in Supplementary Table S6
(‘Materials and Methods’ section). Consistent with the
mRNA level changes, a much higher number of reactions
were predicted active in adipocytes than in preadipocytes
(556 compared with 290, respectively) with 259 reactions
predicted to become active during differentiation. Five
pathways with highest predicted activation between
preadipocytes and adipocytes were cholesterol metabolism
(76% reactions predicted to change), fatty acid activation
(64%) and oxidation (93%), triacylglycerol synthesis
(60%) and branched chain amino acid (BCAA: valine,
leucine, isoleucine) metabolism (50%) (for metabolites
and enzymes involved refer to Supplementary Table S7),
highly involved in lipid metabolism and metabolic
diseases, suggesting the ability of the approach to
recapitulate adipocyte characteristics. On a metabolite
level, these pathways converge at acetyl-CoA, which can
produce intermediates to be converted to fatty acids or to
be consumed in the energy-producing mitochondrial
oxidation. Pathways excluded from further analysis
contained reactions predicted undetermined in one of the
two phenotypic states, concretely, heme biosynthesis
with 10 reactions, all predicted active in adipocytes, but
nine of them undetermined in preadipocytes; heme
degradation with only two reactions, both predicted
active in adipocytes but undetermined in preadipocytes
and the biosynthesis of tyrosine, phenylalanine
and tryptophan, which contains only one
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reaction (O2+L-Phenylalanine+Tetrahydrobiopterin
-> Tetrahydrobiopterin-4a-carbinolamine+L-Tyrosine),
predicted active in adipocytes and inactive in
preadipocytes.
More than 300 metabolic reactions are predicted to
change from preadipocytes to adipocytes (Supplementary
Table S6). In agreement with an increased gene expression
for the majority of metabolic genes, most reaction changes
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Figure 2. Gene metanodes reveal frequent TF association to disease-relevant genes exempliﬁed by nitric oxide synthases in HUVEC data. The result
of disease enrichment tests for genes associated with 1–10 TFs are shown (A), where the horizontal line corresponds to hypergeometric P <0.01. The
endothelial relevant diseases (diamonds) is compared with all diseases (triangles). (B) The three enzymes encoding nitric oxide synthases (NOS1,
NOS2 and NOS3) and the two reactions that convert L-arginine to NO for regulating vascular dilation are shown. Data related to genes are
displayed in gene metanodes superimposed on the metabolite-reaction network. Peak associations from 10 ChIP-seq studies in HUVECs (ETS1,
MEF2C, p65, FLI1, HIF1a available via NCBI SRA and cMYC, GATA2, MAX, cJUN, cFOS and input available via ENCODE) are displayed in
the indicated order where color indicates TF association and the respective TF signal tracks are shown in C. The value range 1–100 is used in the ﬁrst
ﬁve tracks and 1–78 in the ENCODE tracks.
Table 1. Endothelial disease relevant genes exposed by association to multiple TFs in HUVEC data
Symbol Pathway Entrez GeneID Number
of disease
Number
of TFs
NOS3 Arginine and proline metabolism 4846 140 8
PTGS2 Eicosanoid metabolism 5743 97 8
HMOX1 Heme degradation 3162 56 8
ABCA1 Transport, extracellular; transport, golgi apparatus 19 20 9
PTGS1 Eicosanoid metabolism 5742 12 8
LIPG Triacylglycerol synthesis 9388 9 10
ADA Nucleotides; purine catabolism 100 9 9
PDE4D Nucleotides 5144 9 8
PDE4B Nucleotides 5142 8 9
ABCC4 Transport, extracellular 10 257 7 9
PDE3A Nucleotides 5139 7 8
PIK3CG Inositol phosphate metabolism 5294 7 8
SLC12A2 Transport, extracellular 6558 6 9
PAFAH2 Glycerophospholipid metabolism 5051 4 9
GCLM Glutathione metabolism 2730 3 10
MTHFD1L Folate metabolism 25 902 3 10
GALNT2 O-glycan biosynthesis 2590 3 9
PPAP2B Triacylglycerol synthesis 8613 1 10
NNMT NAD metabolism 4837 1 10
The 19 Recon1 metabolic genes annotated with endothelial-relevant disease terms in the DisGeNET database (32) and having an active TSS mark
(H3K4me3) with putative binding of at least 8 TFs from ChIP-Seq HUVEC studies (see ‘Materials and Methods’ section for details) are presented.
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predicted are activations, especially those in lipid metabol-
ism pathways. The BCAA metabolism pathway appeared
as the most affected nonlipid pathway based on the
predictions.
Genome-wide measurements of transcriptional,
posttranscriptional and chromatin-level regulation in
adipocytes
We performed a diverse set of genome-wide measurements
from SGBS adipocytes, summarized in Figure 4A. We ﬁrst
focused on identifying the most highly induced TFs and
their putative targets. In agreement with metabolic gene
expression changes, a highly dynamic TF expression
proﬁle is also observed (Figure 4A). Among the highest
upregulated TFs (see Supplementary Table S8), PPARG
and CEBPA have been previously associated with a key
role in adipocyte differentiation and global regulation of
metabolic genes (8,40,41). The most upregulated TF gene
was the signal responsive LXRA (also known as NR1H3),
an established regulator of cholesterol reverse transport
(42) for which the genome-wide occupancy has not yet
been studied in adipocytes. We obtained the genome-
wide binding proﬁles of PPARg, CEBPa and LXRa to
reveal their possible interplay in SGBS adipocytes, by
collecting ChIP samples for sequencing (ChIP-seq). We
also included published primary adipocyte (day 9) (10)
and SGBS PPARg (day 20) (41) data sets retrieved from
the Sequence Read Archive database for comparison. The
ChIP-seq reads that satisﬁed quality criteria were aligned
to the hg19 human genome (see ‘Materials and Methods’
section for details). Statistics about initial and ﬁnal read
numbers are indicated in Supplementary Table S2.
In addition to regulation of the transcriptional output,
the measured expression changes of metabolic genes could
also be controlled at the posttranscriptional level. In par-
ticular, miRNAs have emerged as important regulatory
molecules and regulation of a number of miRNAs have
been described as important for successful adipogenesis
and lipid accumulation (43). We hypothesized that differ-
ent miRNAs that become down-regulated during
adipogenesis might contribute to allow the observed
upregulation of metabolic genes to take place, serving as
gatekeepers in preadipocytes. To investigate this possibil-
ity, we performed microarray proﬁling to detect differen-
tially regulated miRNAs on days 0, 1, 3 and 12 of
differentiating SGBS cells, revealing several candidate
miRNAs for further analysis (Supplementary Figure S4).
We focused on miRNA clusters with several members re-
pressed already at early stages of differentiation, which
lead to the selection of miR-27a that has previously been
studied in mouse models, and two miRNAs whose role in
adipocytes has not been characterized, miR-29a and miR-
222 for further experiments. Their downregulation was
validated by RT-qPCR to occur already by day 5 of dif-
ferentiation (Figure 4B). To identify candidate target
genes, we performed a miRNA mimic transfection (cor-
responding to a speciﬁc overexpression of each miRNA)
at day 4 of differentiation and analyzed by microarrays
the mRNA proﬁles at 24 h posttransfection and compared
these with the cells similarly transfected with a scrambled
control siRNA. An analysis for enriched heptamer motifs
in 30-UTRs of the downregulated mRNAs from the micro-
array analysis at day 5 reveals enrichment of motifs com-
plementary to respective miRNA seed sequences (Figure
4C and D), suggesting that the observed mRNA
downregulation could be due to their direct targeting by
the miRNA.
Finally, we used the H3K4me3 chromatin modiﬁcation,
indicative of the transcriptional potential of the associated
TSS, to evaluate changes in chromatin state of metabolic
genes. We collected ChIP samples from undifferentiated
and differentiated SGBS cells for sequencing and analyzed
the ChIP-seq data obtained and public data from primary
preadipocytes and adipocytes (10,41).
Predicted target gene proﬁles and their overlap
The comparison of all genes (in A) or metabolic genes
(in B) associated to each TF is shown in Figure 5.
Figure 5C shows the intersection of metabolic genes
associated with PPARg in the three independent data
sets (1278). This ﬁrst genome-wide mapping of LXR
binding in human adipocytes revealed 2117 associated
putative target genes. For CEBPa, we obtained 6880
putative target genes, while for PPARg, the 11 078
putative target associations kept reﬂect peak associations
that were found in our data set and observed in at least
one of the two public data sets (10,41). From these genes,
1691 were associated with peaks from all three TFs
(Figure 5A, Supplementary Table S3), with 147 common
metabolic putative target genes.
To evaluate TSS activity changes, we analyzed the
H3K4me3 ChIP-seq data using a mixture model method
(34) that separates histone marker labeled gene TSS from
those lacking the marker (Supplementary Figure S5) based
on their read count distribution estimates. According to
this analysis, most genes did not completely switch their
TSS activation state during differentiation in SGBS cells
(15 263 active; 19 311 inactive; 470 unclassiﬁed), while
among the transcripts with altered TSS activity, the
H3K4me3 marker mostly decreased: 1223 metabolic
gene TSS are labeled with H3K4me3 in both preadipo-
cytes and adipocytes, 1125 are inactive, TSS activity
decreased for 37 transcripts (corresponding to 25 gene
loci) while only 2 gained the activity marker (Figure 5D
and Supplementary Table S9). As indicated, there was
considerable agreement between primary adipocyte (10)
and SGBS data (Supplementary Table S9).
The large intersection of TF-associated genes with the
metabolic genes from Recon1 (1069 out of 1496 genes,
Figure 5B) suggests a high contribution of these 3 TFs
to the metabolic changes observed on terminal adipocyte
differentiation. Interestingly, the metabolic pathways with
most changes (those highlighted in Figure 3) show exten-
sive TF binding. The acyl-CoA synthetase long-chain
family member 1 (ACSL1) gene of the fatty acid activation
pathway was among the top genes associated with high-
occupancy binding sites for all three TFs (Figure 5E). The
co-localized binding seen in Figure 5E was rather excep-
tional; genome-wide overlap in peak regions by all three
TFs occurred only at 223 peak locations. At gene ontology
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(continued)
term level (Supplementary Table S3), the TFs overlap in
regulation of cholesterol efﬂux. Several genomic regions
each bound by one or several of the TFs studied
concentrated in the vicinity of ATP-binding cassette, sub-
family A member 1 (ABCA1) a key gene in cholesterol
reverse transport (Figure 5G). Interestingly, ACSL1 is
required for oleate- and linoleate-mediated inhibition of
cholesterol efﬂux through ABCA1 in macrophages
indicating cross-talk between the pathways (45). ChIP-
qPCR validation from independent immunoprecipitations
is shown for the two regions indicated (Figure 5F and H),
and the CDH1 and FABP4 loci that served as a negative
and positive control region, respectively, are shown in
Supplementary Figure S6.
Next we identiﬁed target genes for each miRNA based
on repression in the array experiment and a seed match
analysis (putative targets are indicated in red in Figure 4
and listed in Supplementary Table S10), ranging from 65
(miR-222) to 134 (miR-29a) signiﬁcant target calls per
miRNA. Figure 5I shows the metabolic target genes of
each miRNA overlapped with TF target association lists
(those genes that are signiﬁcantly regulated during differ-
entiation are indicated with a star).
Interestingly, those putative miR-27a and miR-222
targets that are overlapping with more than one TF are
in fact mainly associated with high-occupancy binding,
namely PISD, CYP1B1, the mitochondrial glycerol-3-phos-
phate acyltransferase (GPAM), hexokinase 2 (HK2), LPL,
RPIA, the C-4 to C-12 straight chain acyl-CoA dehydro-
genase (ACADM) and stearoyl-CoA delta-9-desaturase
(SCD), suggesting that key metabolic genes are under
tight combinatorial transcriptional and posttranscrip-
tional regulation. Interestingly, the DisGeNET resource
reports a disease association for each of these genes,
only HK2 is not supported by this data source but in
light of recent literature is implicated in cancer (46,47).
All but two putative miRNA targets were also associated
with TF-mediated regulation. Moreover, as previously
reported (17,16), we could conﬁrm PPARG among the
miR-27a targets in adipocytes. There is also overlap
between the miRNAs: according to our analysis miR-
27a and miR-222 both target CYP1B1, miR-27a and
miR-29a target the amino acid transporter solute carrier
family 7 member 5 (SLC7A5) while miR-29a and miR-222
target dihydrolipoamide branched chain transacylase E2
(DBT).
In conclusion, the putative shared TF and miRNA
target genes that our data integration revealed were
ACADM, DBT, GPAM, HK2, LPL and SLC7A5.
Taken together, by collecting a diverse and comprehensive
set of regulatory data on adipocyte differentiation we were
able to show that enzymes crucial or rate limiting for lipid
metabolism were often associated with miRNAs and high
occupancy binding by multiple TFs, suggesting tight
combinatorial effects of TF upregulation and miRNA
downregulation driving metabolic changes in
adipogenesis.
Cell fate determining TFs engage signal-dependent TFs in
a feed-forward motif
Defects in adipocyte differentiation represent an import-
ant early event in obesity and related metabolic dysfunc-
tion. To address the role of cell fate master regulators
interfacing the metabolic and regulatory networks,
heatmaps showing the top-ranked upregulated TFs ac-
cording to differential expression between day 12 and
day 0 are shown in Figure 6A. Focusing on target gene
associations to high occupancy binding by the three TFs
(lines connecting the studied TFs to upregulated genes),
the prominent role for PPARg in regulating other TFs in
adipogenesis becomes apparent. Notably, each TF studied
here binds its own regulatory region, while CEBPa and
LXR show few high-occupancy interactions to the other
upregulated TFs, in contrast to PPARg. In fact, the only
other TF association is the LXR binding to SREBF1.
We conﬁrmed the binding of LXR to the prominent
LXR peaks in the SREBF1 locus by ChIP-qPCR in adi-
pocytes (enrichment was also observed for CEBPa), while
the prominent PPARg peak further upstream is supported
by all three ChIP-seq studies (Figure 6B). According to
our data, the cell fate regulating TFs form two closely
connected feed-forward motifs to these two signal respon-
sive TFs, both known to play key roles in cholesterol me-
tabolism, with PPARg associated to SREBF1 through
both LXR and CEBPa (Figure 6A and Supplementary
Figure S7).
As a representative of a ligand-responsive candidate
drug target TF, we examined the high-occupancy LXR
binding sites and conﬁrmed binding to 11 previously
reported LXR targets (Supplementary Table S3 in bold).
Notably, all these genes were also upregulated during dif-
ferentiation. To test the ligand-responsiveness of genes in
the loci occupying the LXR binding sites (<500 kb from
the TSS), we performed a microarray with the LXR
agonist T0901317 (Supplementary Table S11) from a 4-h
ligand stimulation of differentiated SGBS cells and could
Figure 4. Continued
RT-qPCR analysis. (B) RT-qPCR analysis of the relative expression values of the endogenous miR-27a, miR-29a and miR-222 from undifferentiated
and 5-day differentiated SGBS cells. The measured expression values were normalized to U47 snRNA and are shown relative to undifferentiated
cells, value of which was set to 1 (gray bars). Data points indicate the mean expression values of triplicate experiments and the error bars represent
SD. Student’s t-test was performed to determine the signiﬁcance of downregulation on differentiation (*P< 0.05; **P< 0.01; ***P< 0.001). (C)
Enrichment analysis of heptamer motifs in the 30-UTR sequences of signiﬁcantly downregulated transcripts. The count of all possible heptamer
motifs (each represented by a circle) and their log2-enrichment within the 30-UTRs of downregulated transcripts are depicted on the x-axis and y-axis,
respectively. The signiﬁcantly enriched heptamers are marked in red. The most enriched abundant heptamers are corresponding to the reverse
complement sequences of the overexpressed miRNA seeds as indicated (see ‘Materials and Methods’ section for details). (D) MA-plot depicting the
log2-expression levels (x-axis) of all transcripts in cells transfected with indicated miRNA mimics and the log2-fold change relative to cells transfected
with siCtrl. The signiﬁcantly downregulated transcripts (unadjusted P< 0.01, log2-fold change<0.3) containing at least one putative binding site
for the respective miRNA are marked in red. The total number of putative miRNA targets is indicated (with metabolic target genes in brackets).
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Figure 5. Overlaps in the genome-wide target proﬁles of PPARg, CEBPa, LXR and the miRNAs 27a, 29a and 222 from SGBS adipocytes.
Venn diagrams comparing putative target genes for PPARg, CEBPa and LXR (in A and B) or between different studies that proﬁle PPARg binding
(B) as obtained using the GREAT tool (36) are shown. Among all genes (A), 1691 genes are associated with all TFs, representing a large fraction
from each individual TF peak-gene association list. Metabolic genes (C) show a similar highly overlapping target association proﬁle. (C) In total, 606
PPARg target associations to metabolic genes are supported by ChIP-seq data from day 10 and day 20 differentiated SGBS cells (41) and day 9
differentiated primary adipocytes (44), with an additional 419 metabolic genes supported by at least two data sets. The pie chart (D) illustrates how
many genes gain or lose the H3K4me3 signal, showing that most genes retain their activity marker status. (E) The ChIP-seq signal tracks from
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validate 39 additionally ligand-responsive genes at this
early time point (Supplementary Table S12). Among
known target genes, MYLIP1, SREBF1, ABCA1 and
ABCG1 were signiﬁcantly ligand responsive at this time
point, while the upregulation of stearoyl-CoA delta-
9-desaturase (SCD) was modest and did not pass the
multiple testing correction (unadjusted P< 0.05). New
putative target associations to ADH1B, TMEM17 and
WSB1 were supported by the array data and high-
occupancy binding sites. However, the majority of respon-
sive genes were associated with less-prominent LXR
binding under the unstimulated condition represented by
the ChIP-seq experiment, including ELOVL6, LIPA,
SCARB1, HSD17B7 and LPIN1 that function in lipid
metabolism. Therefore, ligand stimulation greatly
impacts LXR-mediated regulation of the metabolic
network, in agreement with observations from mouse
liver (49).
The interaction of PPARg, LXR and SREBF1 has been
studied before on selected target genes (50), and therefore
our focus here was how they interact on pathway level.
First, to conﬁrm that SREBF1-mediated regulation con-
verges with the pathways observed to change most during
adipogenesis (Figure 3 and Supplementary Figure S2), we
obtained a list of SREBF1-regulated genes observed in
human myocytes (48). Cholesterol metabolism was the
most signiﬁcant pathway (hypergeometric P=3.15e-06,
Supplementary Table S13). The TF feed-forward circuits
additionally engage the acyl-CoA synthetase enzyme
genes, namely ACSL3, 4, 5 (Supplementary Figure
S8) and the previously highlighted ACSL1 (Figure 5), in
fatty acid activation that fuels triglyceride synthesis.
The integrative pathway map of cholesterol metabolism
is shown in Figure 6C. Red edges represent predicted
reaction activation from the preadipocyte state and
black edges represent reactions predicted inactive. A
detailed description of all the components can be found
in the ﬁgure legend. In short, ﬁlled shapes indicate the
putative binding of a TF (polygons on the right) or the
presence of the active TSS marker (circles above) from
ChIP-seq data. The central heatmaps display the
discretized gene expression (below) and the reaction
activity during differentiation as predicted by the mathem-
atical model (above).
Based on the microarray data, all genes participating in
the active branch of the cholesterol synthesis pathway,
except CYP51A1, show an increased expression on
differentiation. RT-qPCR validation for eight induced
genes is displayed in Figure 6D. Genes involved in the
inactive branch, namely 3-hydroxy-3-methylglutaryl-CoA
(HMGC)-lyase-like-1, HMGC-synthase-2, SLC25A16
and SOAT1, show a constant low level of expression. To
place the candidate regulatory motifs including SREBF1
(Supplementary Figure S7) in context of the ChIP-seq
data, we used these integrative pathway maps to check
which expression proﬁles potentially reﬂect more
complex dynamics that can be achieved through feed-
forward motifs by identifying those that could not be
explained by simple direct binding by the three most up-
regulated TFs selected for ChIP-seq.
Binding sites for at least one of the three TFs were
associated to most genes in the pathway (81%). PPARg
has high-occupancy binding sites in the vicinity of
HMGC-synthase 1 and mevalonate kinase (MVK)
indicating that it may have a predominant role in
regulating these enzymes at key upstream reactions of
the synthesis pathway (Figure 6C, upper left corner).
All TFs bound nearby the HMGC-reductase (HMGCR)
gene locus encoding the rate limiting enzyme and
gene loci encoding enzymes of the initial steps of the
alternative ketogenesis pathway (mitochondrial) that
start by producing HMGC from acetyl-CoA and
acetoacetyl-CoA, namely HMGC-synthase 2 and
HMGC-lyase-like-1. Concordant regulation by SREBF1
observed in myocytes concentrates on HMGCR, and, in
particular, on the central and terminal parts of the
pathway, including all genes starting from MVD.
Among these, ﬁve were not bound by the other TFs in
the ChIP-seq data, suggesting that their upregulation
occurs indirectly via the regulation of SREBF1. These
include farnesyl diphosphate synthase (FDPS) that has
been reported to synthesize isoprenoid natural ligands
for PPARg (51), constituting a putative metabolite
positive feedback loop. Interestingly, nodes associated to
multiple TFs reappear at the end of the synthesis pathway
(lower left corner) at the dehydrocholesterol reductases
(DHCR)-7 and 24 loci, the latter being a known LXR
target gene (52) in addition to ABCA1. However, only
ABCA1 is signiﬁcantly up-regulated in the microarray
after 4 h of ligand stimulation (Supplementary Table S11
and S12), which suggests that more complex dynamics
may be used to control the terminal step of the pathway
at the DHCR24 locus.
In summary, a tight regulatory circuit between TFs ne-
cessary for adipocyte differentiation and those implicated
in proper cholesterol homeostasis was observed and
associated with the major lipid synthesis pathways.
More generally, analyzing TF binding in context of the
metabolic network allows formulating testable hypothesis
about the regulatory mechanism.
Figure 5. Continued
PPARg studies in SGBS cells (41) and primary adipocytes (44), CEBPa and LXR from SGBS adipocytes and H3K4me3 from primary and SGBS
cells are displayed at the ACSL1 locus that shows high-occupancy binding of PPARg, CEBPa and LXR. The ChIP-qPCR validation comparing
enrichment with speciﬁc antibody to IgG unspeciﬁc control for the PPARg and CEBPa occupied region indicated is shown in (F). (G) Similarly as
above, the TF signal tracks show multiple peaks at the ABCA1 locus including the LXR response elements that show signiﬁcant enrichment also with
PPARg and CEBPa antibodies as validated using ChIP-qPCR in (H). The enrichment values are shown relative to the enrichment of IgG and
indicate the mean enrichment values of triplicate experiments and the error bars represent SEM. One sample t-test was performed to determine the
signiﬁcance of TF enrichment compared with IgG (*P< 0.05; **P< 0.01). (I) Venn analysis of metabolic target genes of the tested miRNAs and their
targeting by TFs. The lists of metabolic genes targeted by the individual miRNAs and by the TFs PPARg, CEBPa or LXR are overlapped to identify
the metabolic genes under combinatorial multilevel regulation. The genes signiﬁcantly changing during SGBS differentiation are indicated with a star.
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Figure 6. Integrated analysis of the regulation of the cholesterol synthesis pathway. (A) The average logarithmic fold change values from 4, 8 and
12 h and days 1, 3 and 12 of differentiation displayed as a heatmap and sorted based on day 12 values identify LXRA (NR1H3), CEBPA and
PPARG as the most upregulated TF genes. Association to high-occupancy ChIP-seq peaks of PPARg, CEBPa and LXR in SGBS cells are indicated
with colored lines identifying autoregulation of each TF, regulation of SREBF1 by LXR and PPARg, of CEBPD and PPARG by CEBPa and
regulation of majority of TF genes shown by PPARg. (B) The ChIP-seq signal tracks as in Figure 4 are shown at the SREBF1 locus. Regions with
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Convergence of miRNAs and TFs exposes further
disease-relevant nodes
Our data also revealed several convergence points of
miRNAs and TFs on metabolic genes (Supplementary
Figure 5I). Figure 7 shows the BCAA catabolism
pathway that represents the main nonlipid pathway high-
lighted here. The early steps include several genes that are
upregulated during differentiation, two of which are po-
tentially targeted by all three TFs studied, the branched
chain keto acid dehydrogenase E1 beta (BCKDHB) and the
dihydrolipoamide dehydrogenase (DLD), while DBT is a
putative target of PPARg, CEBPa, miR-222 and miR-
29a. Together with BCKDHA, these genes in fact encode
for the large protein complex called branched-chain alpha-
keto acid dehydrogenase. According to our results, this
enzyme complex is the key regulatory point under the
control of multiple regulators and an interesting target
for further analysis. Moreover, the cytosolic branched
chain aminotransferase 1 (BCAT1) that catalyzes the ﬁrst
steps of the BCAA turnover in cytosol is associated with
all 3 TFs. The upregulated genes downstream include
propionyl CoA carboxylase beta (PCCB) and
methylmalonyl CoA epimerase (MCEE) whose genomic
loci are occupied by both PPARg and CEBPa and
PCCA that is associated to all three TFs. Thus, similarly
to cholesterol synthesis pathway, the TFs studied converge
especially at the initial and terminal steps of the pathway,
with the added complexity of posttranscriptional regula-
tors at the large main enzyme complex. As described
earlier, the SLC7A5 gene that functions in BCAA trans-
port is targeted by two miRNAs (miR-27a and miR-29a).
The BCAA pathway from HUVECs is shown in
Supplementary Figure S9. Among the miRNA target
proﬁles available from HUVECs, a study of miR-663
targets reported regulation of SLC7A5 (54), and
moreover, 9 out of 10 TFs in HUVECs were associated
with this gene. As in adipocytes, the BCAT1 gene is
associated with multiple TFs in HUVECs revealing key
similarities between the regulator proﬁles and multi-regu-
lator nodes of these cell types.
To visually assess the convergence of the studied TFs
and miRNAs on the other highly activated metabolic
pathways, we extended gene metanode metabolic maps
to two additional pathways (fatty acid oxidation in
Supplementary Figure S8 and triglyceride synthesis in
Figure 8). All ﬁve maps, as well as the remaining 94
pathways in Recon1, and associated data can be inter-
actively explored in our IDARE web portal (http://
systemsbiology.uni.lu/idare.html).
MiR-27a is known to engage in the main TF circuitry
through the inhibition of PPARg (15–17). The triglyceride
pathway was identiﬁed to contain multiple shared target
associations, as shown in Figure 8. The regulatory associ-
ations from TFs and miRNAs converge along the
pathway at three key enzymes: (i) GPAM that catalyzes
the initial and committing step in glycerolipid biosynthe-
sis, playing a pivotal role in the regulation of cellular
triacylglycerol and phospholipid levels (57), (ii) LPIN1
that catalyzes the penultimate step in triglyceride synthesis
including the dephosphorylation of phosphatidic acid to
yield diacylglycerol (23) and (iii) LPL that catalyzes the
release of fatty acids from triglycerides (24) [extracellular
LPL facilitates fatty acid import, whereas also intracellu-
lar activity has been observed that could serve in fatty acid
export (58)]. The enzymes from reactions directly
connected to these highly regulated gene nodes are also
upregulated and associated with PPARg (and some
CEBPa) binding, including the AGPAT gene family
members (directly downstream GPAM), the
triacylglycerol synthesizing DGAT1 and DGAT2, and the
lipase MGLL, supporting a tight transcriptional regula-
tion of triglyceride synthesis spread across the pathway.
We selected the GPAM locus for further validation experi-
ments, as it was the ﬁrst enzyme targeted by both TFs and
miR-27a. We could conﬁrm binding to several prominent
peaks upstream of the GPAM locus (Figure 8B and C).
Furthermore, miRNA motif analysis of the 30UTR
revealed two miR-27a binding sites, one of which corres-
ponds to a conserved site that has been shown functional
in mice (56). In agreement, transfection with miR-27a
mimic, but not that of mir-29a or mir-222, signiﬁcantly
decreased GPAM mRNA levels (Figure 8D).
Finally, we also examined the H3K4me3 data in context
of the pathways identiﬁed to change most. A reciprocal
change in the TSS activity affecting carbohydrate and
lipid metabolism was observed for two genes encoding
enzymes involved in glycerol metabolism: the glycerol-
3-phosphate dehydrogenases GPD1 and GPD2. Glycerol-
3-phosphate (G3P) can be synthesized from glucose via an
intermediate step that forms dihydroxyacetone phosphate
Figure 6. Continued
high enrichment for one or several TFs were selected for validation by ChIP-qPCR (numbered in the ﬁgure). The enrichment values using antibodies
against all three TFs are shown relative to the enrichment of IgG and indicate the mean enrichment values of triplicate experiments and the error
bars represent SEM. One sample t-test was performed to determine the signiﬁcance of TF enrichment compared with IgG (*P< 0.05; **P< 0.01). (C)
The metabolic pathway of cholesterol synthesis is shown with several omics data overlayed extending the metanode features presented in Figure 2.
The pathway starts with the condensation of acetyl-CoA (accoa[c]) and acetoacetyl-CoA (aacoa[c]) to form 3-hydroxy-3-methylglutaryl-CoA
(hmgcoa[c]) catalyzed by HMG-CoA synthase encoded by the gene HMGCS1. The end point metabolite is cholesterol (chsterol[r][m][c][e], r—
endoplasmic reticulum, m—mitochondria, c—cytosol, e—extracellular). The start and end reactions are indicated by a thicker arrow and genes
discussed further in the text are shown as larger metanodes for clarity. For details of heatmap, node and edge descriptions, see Figure 1, and for a
complete list of metabolite names, Supplementary Table S7. Here, regulation in the SREBF1 microarray (48) is indicated by purple lining of the
node. The reaction activity heatmap is blank if the gene is associated to multiple reactions with different predicted activity and in those cases the
respective reaction activity heatmaps can be found below the pathway with the reaction naming matching those shown on the pathway. (D) RT-
qPCR validation of the relative expression values of selected genes from the cholesterol synthesis pathway during SGBS differentiation. The
measured expression values are shown normalized to RPL13A mRNA and relative to undifferentiated cells (set to 1). Data points indicate mean
expression values of triplicate experiments and the error bars represent SEM. Student’s t-test was performed to determine the signiﬁcance of
upregulation (*P< 0.05).
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(DHAP). This metabolite and NADH are converted
to G3P by GPD1, and G3P can subsequently be
converted to lipids (55). GPD1 increased H3K4me3
levels in differentiated cells, also in primary adipocytes
(Figure 8E), matching its expression proﬁle with a
7.9-fold increase in transcription (Supplementary
Table S5). GPD2 in turn can convert G3P to quinone to
fuel mitochondrial oxidation; in agreement with a shift to
lipogenic metabolism its TSS activity was repressed
(Figure 8E) and a low level of expression maintained.
Altogether, we obtained four novel genome-wide target
gene proﬁles associating the TF LXRa and the miRNAs
27a, 29a and 222 with their likely target genes in
human adipocytes to support the analysis performed
using public data of TF binding for additional 12 TFs
from adipocyte and endothelial cells. Such data on
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Figure 7. Integrated metabolic pathway of BCAA metabolism. The BCAA (valine, leucine and isoleucine) metabolism pathway is shown. The
metanode and edge representation is identical to Figure 6. While leucine degradation is predicted inactive in both preadipocytes and adipocytes
(left part), the degradation of both valine and isoleucine is predicted to become active in adipocytes (red edges). The respective end products acetyl-
CoA and succinyl-CoA can be fed into the TCA cycle. The important intermediates malonyl-CoA and acetoacetate link to lipogenesis or ketone
body formation, respectively. This pathway has similarities with FAO, sharing the enzyme ACADM and the metabolite propionyl-CoA (ppcoa[m]).
The metanodes indicate that two nodes are associated with both TFs and miRNAs: The component of the large multienzyme complex, DBT, is
associated with PPARg, CEBPa, miR-29a and miR-222, while among BCAA transporters contained in Recon1, SLC7A5 is associated to PPARg,
miR-27a and miR-29a. The genes discussed further in the text are shown as larger metanodes for clarity.
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mitochondrial GPD2 functions in a catabolic pathway that fuels the TCA cycle, whereas GPD1 plays a role in triglyceride synthesis. The initial and
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regulatory factors are highly relevant to describe their role
in different cell types and potentially in driving disease.
However, often the volume of data from genome-wide
assays hinders tangible conclusions to be drawn. We
provide here an easily accessible tool to analyze links
between the metabolic and regulatory networks, to
identify different regulatory mechanisms at the pathway
level and for the discovery of key nodes as demonstrated
here using the convergence of regulators to highlight such
genes in the two cell types.
DISCUSSION
Despite the growing amount of data collected from gene
expression studies, a common framework or a model to
capture the key systems properties is often lacking. Here,
we collect a comprehensive data set from own experiments
and public data focusing on two key cell types implicated
in the pathogenesis of metabolic syndrome, namely endo-
thelial cells and adipocytes. To study in an integrated
manner how components of transcriptional and posttran-
scriptional regulation impact the expression of metabolic
genes, we introduce gene metanodes and the web portal
IDARE (Integrated Data nodes of Regulation) for inter-
active data exploration of various data types within the
metabolic network context.
The endothelium-derived relaxing factor NO and the
catalyzing enzymes nitric oxide synthases that generate
NO from the amino acid L-arginine represent a key dis-
covery in CVD research. Together with genes implicated
in hereditary monogenic disease (ALDH4A1) (38) or in
recent GWAS studies (MTAP) (39), these enzymes from
the arginine-proline metabolic pathway represent those
associated with most TF binding in our analysis of 10
ChIP-seq studies from HUVEC cells.
TFs represent key factors to establish a cellular pheno-
type; however, they do not function in isolation. For a
more comprehensive view, the analysis was extended
from TFs to include the evaluation of chromatin marker
levels and miRNAs. Three most upregulated TFs
(PPARg, CEBPa and LXRa) and prominent members
of miRNA families (miR-27a, miR-29a and miR-222)
downregulated on adipocyte differentiation were selected
for genome-wide analysis. We validated the combinatorial
binding in ChIP-qPCR and repression of mRNA using
miRNA mimics for GPAM, representing a gene associated
with TF and miRNA binding at a committing step in
glycerolipid biosynthesis. Supporting the relevance of
maintaining tight regulation of its expression level,
Brockmo¨ller et al. (59) reported a signiﬁcant association
between lowered GPAM mRNA levels and poor survival
in breast cancer, a misregulation that in context of our
results could be linked to the increased expression levels
of miR-27a reported in invasive breast cancers (60). These
results are highly supportive of the relevance of regulatory
associations following the approach used here. However,
mammalian regulatory regions may overlap and span
across gene boundaries resulting inevitably in some false
target gene associations. As further possible caveats,
target mRNA dynamics impact detection of the miRNA
regulatory effect and ChIP-seq signal only implies TF
binding that constitutes a necessary, but not sufﬁcient,
condition to alter mRNA synthesis.
Despite possible inaccuracies in representing true regu-
latory interactions, the integrated analysis on metabolic
pathway regulation clearly implicated the dyslipidemia
loci LPL (24) and LPIN1 (23) as well as LDLR (22) (the
latter is missing from Recon1), each associated with
multiple TFs and miRNAs. Furthermore, the GPD1
locus that we identify among genes with increased TSS
marker levels has recently been described to cause infantile
hypertriglyceridemia (61). Thus, our analysis holds
promise to identify key regulatory nodes that are import-
ant in different diseases by using microarray and
sequencing data that are readily available from multiple
tissues.
Our data extends data collected on PPARg and CEBPa
in human adipocytes (10,40,41,44), while for LXR and
miR-27a, our genome-wide data on target genes are the
ﬁrst reported in human adipocytes and can be compared
with data obtained from liver (49,56) and foam cells (62).
PPARg and CEBPa represent cell fate determining TFs
widely studied in context of adipocytes. However, their
interplay with signal-dependent TFs is less well under-
stood, including LXRa that increased at expression level
most during differentiation. The ﬁrst glimpse to the LXR
genome-wide binding proﬁle through ChIP-seq showed
binding in a few hundred to few thousand regions (high-
versus low-occupancy cutoff), in agreement with a similar
number of binding sites reported from unstimulated
mouse liver cells (49). Most strikingly, among all
upregulated TFs, only SREBF1 was associated with TFs
other than PPARg, being bound by LXR and CEBPa.
The cholesterol synthesis and fatty acid activation
Figure 8. Continued
committing step in glycerolipid biosynthesis is catalyzed by GPAM. GPAM, LPIN1 and LPL are all associated with all three TFs and in addition
GPAM and LPL are targeted by miR-27a. The synthesis of both triacylglycerol and glycerol is predicted to shift to active in adipocytes. The genes
discussed further in the text are shown as larger metanodes for clarity. (B) The ChIP-seq signal tracks as in Figure 5 are shown at the GPAM locus.
Regions with high enrichment for one or several TFs were selected for validation by ChIP-qPCR (numbered in the ﬁgure). Each region was tested for
enrichment using antibodies against all three TFs and IgG as a control as is shown in adjacent plots (C). The enrichment values are shown relative to
the enrichment of IgG and indicate the mean enrichment values of triplicate experiments and the error bars represent SEM. One sample t-test was
performed to determine the signiﬁcance of TF enrichment compared with IgG (*P< 0.05; **P< 0.01). (D) The GPAM 30UTR is shown with miRNA
target predictions from TargetScan. Two binding sites for miR-27a can be seen, one of which is conserved and previously validated in mouse liver
(56). Fold change values from miRNA mimic transfections are displayed from the microarray data. Two sample t-test was performed to determine
the signiﬁcance of silencing compared with siCtrl transfection (**adjusted P< 0.01; ***adjusted P< 0.001). (E) Signal tracks at the vicinity of their
TSS regions of GPD1 and GPD2 show the H3K4me3 ChIP-seq signal from primary preadipocytes and adipocytes (10) compared with SGBS
preadipocytes and adipocytes. At the GPD1 locus, the H3K4me3 signal increases in SGBS and primary adipocytes, whereas a decrease in signal
is observed at the GPD2 TSS in SGBS cells.
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pathways were each associated with this putative multi-TF
feed-forward circuit. It is intriguing that precisely these
pathways have been reported to contribute to generation
of endogenous PPARg ligands (51,63), potentially
providing a metabolite positive feedback to substantiate
transcriptional autoactivation required for cell
differentiation.
On activating signal, our microarray using an LXR
agonist revealed regulation of several genes that in our
ChIP-seq data were initially associated with low occu-
pancy binding. Similar study in mouse liver (49) showed
a dramatic increase in peak height on agonist activation,
suggesting that the ligand-bound receptor may be more
efﬁciently recruited to its genomic target loci. It will there-
fore be of interest to test the ligand-dependent binding
proﬁle also in adipocytes. LXRs have been shown to
play critical roles in the regulation of overall cholesterol
catabolism, absorption and transport in the intestine,
macrophages and liver (42). Furthermore, the LXR
target gene MYLIP that inhibits the LDLR pathway by
targeting LDLR to proteasomal degradation (64) is a
likely target gene of miR-222 according to our microarray
and seed analysis, exposing a CVD-relevant novel regula-
tory factor in the cholesterol intercellular trafﬁcking
pathway.
The miRNA with most interaction with TFs (including
regulation of PPARG) is miR-27a. The regulation of
GPAM by miR-27b was recently described in mouse
liver (56) and is supported by our microarray and
heptamer analysis in human adipocytes. Moreover, we
observe multiple other genes that are posttranscriptionally
regulated along the pathway. These target associations
include the LDLR, LPL and LRP5 that function in lipid
transport. It is worth pointing out that also LPIN1 is
among genes that have a modest downregulation on
miR-27a transfection, in agreement with existence of a
well-conserved binding site in its 30-UTR. However,
further validation is required to ascertain its regulation.
Participation of carbohydrate metabolism in fueling the
triacylglycerol synthesis is supported by the switch in regu-
lation of GPD genes. The upstream enzyme hexokinase-2
that phosphorylates and thereby activates glucose, similar
to GPAM, LPIN1 or LPL, was identiﬁed among the list of
target genes associated with all TFs and miR-27a. Based
on the earlier reports and our combined microarray and
30-UTR heptamer analysis, miR-27 family is establishing
itself as a key miRNA regulator of the triacylglycerol
metabolism.
Interestingly, both miR-222 and miR-29a regulate the
BCKD complex in the BCAA catabolism. Recently,
increased levels of the BCAAs were shown to play an im-
portant role in diabetes (65). In a model proposed by
Newgard (66), and supported by experiments applying
in vivo mouse models (67), an obesity-related decline in
BCAA catabolism in adipose tissue drives the rise of
circulating levels of these amino acids. The model
suggests that readily usable glucose and lipid substrates
may obviate the need for amino acid catabolism in
adipose tissue. However, the mechanism by which
increased supply of these substrates causes downregula-
tion of the BCAA catabolic enzymes is unknown. Drugs
that activate PPARg (thiazolidindiones or TZDs) can
restore expression of the catabolic genes to normal (68),
already suggesting a role of suppressed PPAR signaling in
this metabolic adaptation. The miR-29 family is
implicated in diabetes based on studies of hepatic
gluconeogenesis in diabetic rat models (69). Based on
our data, it will be relevant not only to study PPARg,
but to include CEBPa, miR-27a, miR-29a and miR-222
as other key regulators of this pathway, and by that po-
tentially further elucidate the novel link of the BCAA
pathway to diabetes.
Both miRNAs targeting the DBT subunit of the BCKD
complex according to our data (miR-29a and miR-222)
are upregulated in the adipose tissue of diabetic rats and
are induced by increased glucose levels in mouse adipo-
cytes (70,71). Moreover, the targeting of DBT by miR-29
family has already been validated in other cell types (72),
making the combinatorial repression of DBT by the
miRNAs one likely explanation for lowered catabolism
of BCAAs in diabetic adipose tissue. In addition to the
initial steps of BCAA catabolism, also the BCAA trans-
port step mediated by SLC7A5 appears to be a highly
regulated node possibly contributing to the diabetic
phenotype. On top of being associated as a PPARg
target in our analysis, SLC7A5 appears to be targeted
by miR-27a and miR-29a, both glucose responsive and
induced in diabetic condition (71). The complexity of
SLC7A5 regulation is further increased when looking at
HUVEC data that reveal it as a potential target of as
many as 9 TFs and an additional miRNA (miR-663) in
the endothelial cells and in context of recent literature
implicating it in key metabolic changes required for T-
cell differentiation (73).
As an initial means to discover key pathways, we used
the gene expression levels as soft constraints to obtain
predictions for metabolic activity in Recon1, a generic
model of human metabolism (2,6). Several other
methods for the integration of expression data on
genome scale metabolic networks have been and are cur-
rently being developed (74) and will be important to
benchmark and consolidate the prediction results in
future studies. Transcript-level measurements address the
space of available network states that translational control
and posttranslational modiﬁcations further ﬁne tune [for
HMGCR this is well established (53)]. The metanodes
enable mapping and visualization of further data onto
metabolic pathways, facilitating data exchange and hy-
pothesis-driven research in context of the metabolic
network. Here, two trends in transcriptional regulation
were observed: (i) shared and high-occupancy binding
nearby gene loci of the initial and terminal steps of a
pathway (the cholesterol synthesis and the BCAA
pathways), a type of transcriptional regulation that has
been reported advantageous for fast responses to environ-
mental conditions in pathways with low protein synthesis
cost (75), and (ii) tight regulation spread along the entire
pathway (triacylglycerol synthesis), which might link to
the tight transcriptional regulation on pathways
spanning high cost enzymes (75).
In conclusion, the analysis of genomic and
transcriptomic data linked with a metabolic network
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model is useful as a means to explore high-throughput
data in a global manner, revealing genes implicated in
disease as convergence points of regulation. To focus on
metabolic pathways that differ in activity comparing two
phenotypes, constraint-based modeling to predict active
metabolic pathways can be included. The putative
shared TF and miRNA target genes from pathways
activated during human adipocyte differentiation that
our new data sets revealed were ACADM, DBT, GPAM,
HK2, LPL and SLC7A5. Genes associated with all adipo-
cyte TFs studied further include ABCA1, ACSL1, the
acetyl-CoA acetyltransferase 2 (ACAT2), the BCAT1;
two more genes from the branched-chain alpha-keto
acid dehydrogenase complex, namely BCKDHB and the
DLD; four genes from the cholesterol synthesis pathway
DHCR7, HMGCS2, HMGCLL1, HMGCR; and three
other lipase genes from triglyceride metabolism, namely
lipase C, lipase G and LPIN1. These data can now be
compared with published data sets such as those from
HUVECs using the IDARE tool. Our workﬂow extends
from current routines in which these disparate but com-
plementary types of cellular information are kept apart
and further motivates study of biological processes from
an integrative point-of-view.
ACCESSION NUMBERS
The microarray and deep sequencing data from this pub-
lication have been submitted to the NCBI GEO database
(http://www.ncbi.nlm.nih.gov/geo/) and assigned the iden-
tiﬁer GSE41578 and can be explored in context of the
pathways described using the web resource at http://
systemsbiology.uni.lu/idare.html, including a track hub
for UCSC Genome Browser that allows fast visualization
of ChIP-seq signal tracks at any gene locus.
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